• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TNFα 阻断在免疫检查点抑制剂治疗中的作用:利大于弊,还是弊大于利?

TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?

机构信息

Laura and Isaac Perlmutter Comprehensive Cancer Center at NYU Langone Health, New York, New York.

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.

出版信息

Clin Cancer Res. 2020 May 1;26(9):2085-2086. doi: 10.1158/1078-0432.CCR-20-0387. Epub 2020 Feb 26.

DOI:10.1158/1078-0432.CCR-20-0387
PMID:32102949
Abstract

The impact on survival of steroids and TNFα blockade to treat immune-related toxicity from checkpoint blockade with ipilimumab, nivolumab/pembrolizumab, or combined ipilimumab and nivolumab was assessed using data from a large national database. Using steroids was associated with better survival than the use of TNFα-blocking antibodies such as infliximab..

摘要

使用大型国家数据库的数据评估了使用类固醇和 TNFα 阻断剂治疗伊匹单抗、纳武利尤单抗/帕博利珠单抗或伊匹单抗联合纳武利尤单抗的检查点阻断相关免疫相关毒性的生存影响。与使用英夫利昔单抗等 TNFα 阻断抗体相比,使用类固醇与更好的生存相关。

相似文献

1
TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?TNFα 阻断在免疫检查点抑制剂治疗中的作用:利大于弊,还是弊大于利?
Clin Cancer Res. 2020 May 1;26(9):2085-2086. doi: 10.1158/1078-0432.CCR-20-0387. Epub 2020 Feb 26.
2
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂:黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
3
Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.荷兰黑色素瘤治疗登记处的数据显示,在接受依匹单抗和抗 PD-1 治疗且对类固醇耐药的患者中,使用抗 TNF 药物与生存率降低相关。
Clin Cancer Res. 2020 May 1;26(9):2268-2274. doi: 10.1158/1078-0432.CCR-19-3322. Epub 2020 Jan 27.
4
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.纳武单抗联合伊匹单抗或单独使用纳武单抗治疗晚期黑色素瘤相关的神经系统严重不良事件,包括一组脑炎病例
Oncologist. 2017 Jun;22(6):709-718. doi: 10.1634/theoncologist.2016-0487. Epub 2017 May 11.
5
Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.晚期黑色素瘤患者接受 CTLA-4 阻断后紧接着进行 PD-1 阻断的短期治疗:单中心经验。
Ann Oncol. 2017 Apr 1;28(4):862-867. doi: 10.1093/annonc/mdw692.
6
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.程序性细胞死亡蛋白1或联合程序性死亡蛋白1/细胞毒性T淋巴细胞相关抗原4抑制治疗转移性葡萄膜黑色素瘤的预后因素及结局
Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22.
7
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.标准剂量帕博利珠单抗联合低剂量伊匹单抗治疗晚期黑色素瘤患者(KEYNOTE-029):一项开放标签、Ib 期临床试验。
Lancet Oncol. 2017 Sep;18(9):1202-1210. doi: 10.1016/S1470-2045(17)30428-X. Epub 2017 Jul 17.
8
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.接受免疫检查点抑制剂治疗的黑色素瘤患者的血小板减少症。
J Immunother Cancer. 2017 Feb 21;5:8. doi: 10.1186/s40425-017-0210-0. eCollection 2017.
9
Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.免疫检查点抑制剂癌症免疫疗法相关免疫介导反应的药物警戒评估。
Pharmacotherapy. 2017 Nov;37(11):1383-1390. doi: 10.1002/phar.2035. Epub 2017 Oct 26.
10
Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.免疫检查点抑制剂伊匹单抗、帕博利珠单抗和纳武利尤单抗在肿瘤学中的现状与未来发展方向
Ann Pharmacother. 2015 Aug;49(8):907-37. doi: 10.1177/1060028015586218. Epub 2015 May 19.

引用本文的文献

1
Accelerating the Evolution of Immune-Related Enterocolitis Management.加速免疫相关性小肠结肠炎管理的进展
J Clin Oncol. 2023 Jun 10;41(17):3110-3115. doi: 10.1200/JCO.22.02914. Epub 2023 Apr 11.
2
Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management.在难治性免疫相关不良反应(irAEs)情况下生物制剂与免疫疗法的联合治疗
Front Med (Lausanne). 2022 Jun 30;9:906098. doi: 10.3389/fmed.2022.906098. eCollection 2022.
3
Improved prediction of radiation pneumonitis by combining biological and radiobiological parameters using a data-driven Bayesian network analysis.
使用数据驱动的贝叶斯网络分析结合生物学和放射生物学参数改进放射性肺炎的预测。
Transl Oncol. 2022 Jul;21:101428. doi: 10.1016/j.tranon.2022.101428. Epub 2022 Apr 20.
4
Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment.肿瘤坏死因子在肺癌中的作用:生物学复杂性及治疗抵抗。
Neoplasia. 2021 Feb;23(2):189-196. doi: 10.1016/j.neo.2020.12.006. Epub 2020 Dec 26.
5
Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy.抗 CD40 治疗后,同时或延迟使用抗 TNF 药物会对免疫相关不良事件和抗肿瘤疗效产生不同的影响。
J Immunother Cancer. 2020 Nov;8(2). doi: 10.1136/jitc-2020-001687.